Drugmakers Refuse FTC on “Junk Patent” Crackdown

The ongoing effort by the FTC to remove what it labels improper and inaccurate — or “junk” — listings of drug patents in the FDA’s Orange Book continues, with all cited drugmakers refusing to delist the 300 patents called out by the commission on April 30.
Source: Drug Industry Daily